Eliem Therapeutics ROA 2021-2024 | CLYM
Current and historical return on assets (ROA) values for Eliem Therapeutics (CLYM) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Eliem Therapeutics ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-06-30 |
$-0.07B |
$0.23B |
-46.59% |
| 2024-03-31 |
$-0.02B |
$0.11B |
-13.39% |
| 2023-12-31 |
$-0.04B |
$0.11B |
-30.37% |
| 2023-09-30 |
$-0.04B |
$0.11B |
-32.10% |
| 2023-06-30 |
$-0.05B |
$0.12B |
-35.02% |
| 2023-03-31 |
$-0.06B |
$0.12B |
-40.15% |
| 2022-12-31 |
$-0.05B |
$0.14B |
-31.29% |
| 2022-09-30 |
$-0.05B |
$0.14B |
-31.31% |
| 2022-06-30 |
$-0.05B |
$0.15B |
-29.99% |
| 2022-03-31 |
$-0.05B |
$0.16B |
-29.44% |
| 2021-12-31 |
$-0.05B |
$0.17B |
-45.79% |
| 2021-06-30 |
$-0.03B |
$0.11B |
-125.93% |
| 2021-03-31 |
$-0.03B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
